ALT - Company ID 0001326190
The table below shows Altimmune, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.00K | $20.00K | $426.00K | -$68.00K | $4.41M | $8.19M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $66.43M | $82.23M | $65.80M | $70.54M | $74.54M | $49.77M |
| SG&A |
Altimmune, Inc. reported annual revenue of $41.00K for fiscal year 2025. That is up 105.0% from $20.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $3.24M (FY 2016) to $41.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $28.10M |
| $20.97M |
| $18.14M |
| $17.13M |
| $15.41M |
| $13.21M |
| Operating income | -$94.49M | -$103.17M | -$95.93M | -$87.74M | -$96.91M | -$54.80M |
| Income tax | -$681.00K | - | - | -$197.00K | - | -$5.42M |
| Net income | -$88.09M | -$95.06M | -$88.45M | -$84.71M | -$97.09M | -$49.04M |
| EPS (diluted) | -$1.00 | -$1.34 | -$1.66 | -$1.81 | -$2.35 | -$1.91 |